Hossein Pashaiefar1,2,3, Marjan Yaghmaie1,2,3, Javad Tavakkoly-Bazzaz4, Seyed Hamid Ghaffari1,2,3, Kamran Alimoghaddam1,2,3, Majid Momeny1,2,3, Pantea Izadi4, Marzie Izadifard1,2,3, Amir Kasaeian1,2,3, Ardeshir Ghavamzadeh1,2,3. 1. 1 Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences , Tehran, Iran . 2. 2 Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences , Tehran, Iran . 3. 3 Hematologic Malignancies Research Center, Tehran University of Medical Sciences , Tehran, Iran . 4. 4 Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences , Tehran, Iran .
Abstract
AIMS: Poly (ADP-ribose) polymerase-1 (PARP-1) plays an important role in the repair of damaged DNA and has prognostic significance in a variety of human malignancies. However, little is known about its expression levels and clinical implication in patients with acute myeloid leukemia (AML). MATERIALS AND METHODS: Quantitative reverse transcription-polymerase chain reaction was done to evaluate PARP-1 expression levels in the bone marrow of 65 patients with non-M3 AML and 54 healthy counterparts. The correlation of PARP-1 expression with clinicopathological features of non-M3 AML patients was also analyzed. RESULTS: Non-M3 AML patients have higher PARP-1 expression than the healthy controls (p < 0.01). Patients with adverse cytogenetic risk have higher PARP-1 expression than other cytogenetic risk groups (p = 0.004). The PARP-1 median expression level divided AML patients into PARP-1 low-expressed and PARP-1 high-expressed groups. High expression levels of PARP-1 were associated with worse overall survival (OS) (p = 0.01) and relapse-free survival (RFS) (p = 0.005). Moreover, multivariate analysis revealed that high PARP-1 expression was an independent risk factor for both OS and RFS. CONCLUSIONS: Our results suggest that PARP-1 overexpression may define an important risk factor in non-M3 AML patients and PARP-1 is a potential therapeutic target for AML treatment.
AIMS: Poly (ADP-ribose) polymerase-1 (PARP-1) plays an important role in the repair of damaged DNA and has prognostic significance in a variety of humanmalignancies. However, little is known about its expression levels and clinical implication in patients with acute myeloid leukemia (AML). MATERIALS AND METHODS: Quantitative reverse transcription-polymerase chain reaction was done to evaluate PARP-1 expression levels in the bone marrow of 65 patients with non-M3 AML and 54 healthy counterparts. The correlation of PARP-1 expression with clinicopathological features of non-M3 AMLpatients was also analyzed. RESULTS: Non-M3 AMLpatients have higher PARP-1 expression than the healthy controls (p < 0.01). Patients with adverse cytogenetic risk have higher PARP-1 expression than other cytogenetic risk groups (p = 0.004). The PARP-1 median expression level divided AMLpatients into PARP-1 low-expressed and PARP-1 high-expressed groups. High expression levels of PARP-1 were associated with worse overall survival (OS) (p = 0.01) and relapse-free survival (RFS) (p = 0.005). Moreover, multivariate analysis revealed that high PARP-1 expression was an independent risk factor for both OS and RFS. CONCLUSIONS: Our results suggest that PARP-1 overexpression may define an important risk factor in non-M3 AMLpatients and PARP-1 is a potential therapeutic target for AML treatment.
Authors: Lena Berning; Lisa Scharf; Elif Aplak; David Stucki; Claudia von Montfort; Andreas S Reichert; Wilhelm Stahl; Peter Brenneisen Journal: PLoS One Date: 2019-09-25 Impact factor: 3.240
Authors: Susanne Kossatz; Giacomo Pirovano; Paula Demétrio De Souza França; Arianna L Strome; Sumsum P Sunny; Daniella Karassawa Zanoni; Audrey Mauguen; Brandon Carney; Christian Brand; Veer Shah; Ravindra D Ramanajinappa; Naveen Hedne; Praveen Birur; Smita Sihag; Ronald A Ghossein; Mithat Gönen; Marshall Strome; Amritha Suresh; Daniela Molena; Ian Ganly; Moni A Kuriakose; Snehal G Patel; Thomas Reiner Journal: Nat Biomed Eng Date: 2020-03-12 Impact factor: 25.671
Authors: Paulina Gil-Kulik; Ewa Dudzińska; Elżbieta Radzikowska-Büchner; Joanna Wawer; Mariusz Jojczuk; Adam Nogalski; Genowefa Anna Wawer; Marcin Feldo; Wojciech Kocki; Maria Cioch; Anna Bogucka-Kocka; Mansur Rahnama; Janusz Kocki Journal: BMC Cancer Date: 2020-05-18 Impact factor: 4.430